City Holding Co. increased its position in GlaxoSmithKline plc (NYSE:GSK) by 4.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,138 shares of the pharmaceutical company’s stock after acquiring an additional 2,259 shares during the quarter. City Holding Co.’s holdings in GlaxoSmithKline were worth $2,287,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. D Orazio & Associates Inc. grew its position in GlaxoSmithKline by 200.0% in the 1st quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 400 shares during the last quarter. Reilly Financial Advisors LLC grew its position in GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 255 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in GlaxoSmithKline in the 1st quarter worth $37,000. Orrstown Financial Services Inc. grew its position in GlaxoSmithKline by 210.7% in the 1st quarter. Orrstown Financial Services Inc. now owns 932 shares of the pharmaceutical company’s stock worth $39,000 after purchasing an additional 632 shares during the last quarter. Finally, Riverview Trust Co acquired a new stake in GlaxoSmithKline in the 1st quarter worth $39,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.
In related news, Director Plc Glaxosmithkline bought 385,714 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,399,996.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.
Several analysts have issued reports on the stock. Cowen restated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Morgan Stanley started coverage on shares of in a research report on Monday, June 17th. They set an “equal weight” rating and a GBX 215 ($2.81) target price on the stock. Finally, Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and three have issued a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of $42.66.
Shares of GlaxoSmithKline stock traded up $0.30 during trading on Friday, hitting $41.84. 208,640 shares of the company’s stock traded hands, compared to its average volume of 2,266,365. The company has a current ratio of 0.72, a quick ratio of 0.48 and a debt-to-equity ratio of 6.92. The business’s fifty day simple moving average is $40.54. GlaxoSmithKline plc has a twelve month low of $36.41 and a twelve month high of $42.20. The firm has a market cap of $103.76 billion, a P/E ratio of 13.24, a PEG ratio of 2.17 and a beta of 0.74.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 167.07%. The company had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $9.55 billion. As a group, research analysts predict that GlaxoSmithKline plc will post 2.88 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were paid a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.74%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is presently 58.86%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Fundamental Analysis and Choosing Stocks
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.